title: Portopulmonary hypertension.
abstract: Portopulmonary hypertension (POPH) is the presence of pulmonary arterial hypertension in patients with portal hypertension. Among liver transplant (LT) candidates, reported incidence rates of POPH range from 4.5% to 8.5%. In patients with LT, intraoperative death and immediate post-LT mortality are feared clinical events when transplantation is attempted in the setting of untreated, moderate to severe POPH; therefore, POPH precludes LT unless the mean pulmonary artery pressure can be reduced to a safe level and right ventricular function optimized. Specific pulmonary artery vasodilator medications seem effective in reducing pulmonary artery pressures and improving right ventricular function and survival.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA. Electronic address: cartinceba.rodrigo@mayo.edu.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Cartin-Ceba
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Krowka
mesh_terms: D006328:Cardiac Catheterization; D003937:Diagnosis, Differential; D065627:Familial Primary Pulmonary Hypertension / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D006439:Hemodynamics; D006801:Humans; D006975:Hypertension, Portal / Q000150:complications*; D008103:Liver Cirrhosis / Q000150:complications; D016031:Liver Transplantation; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use; D011652:Pulmonary Circulation; D017466:Receptors, Endothelin; D016278:Ventricular Function, Right
chemical_list: D058986:Phosphodiesterase 5 Inhibitors; D011453:Prostaglandins; D017466:Receptors, Endothelin
keywords: Cirrhosis; Liver transplant; Portal hypertension; Portopulmonary hypertension; Pulmonary hypertension